BioLargo Retained Earnings (Accumulated Deficit) 2010-2024 | BLGO
BioLargo retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
BioLargo Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-147 |
| 2022 |
$-144 |
| 2021 |
$-139 |
| 2020 |
$-132 |
| 2019 |
$-123 |
| 2018 |
$-112 |
| 2017 |
$-101 |
| 2016 |
$-92 |
| 2015 |
$-84 |
| 2014 |
$-79 |
| 2013 |
$-75 |
| 2012 |
$-73 |
| 2011 |
$-67 |
| 2010 |
$-64 |
| 2009 |
$-58 |
BioLargo Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-148 |
| 2024-03-31 |
$-148 |
| 2023-12-31 |
$-147 |
| 2023-09-30 |
$-146 |
| 2023-06-30 |
$-145 |
| 2023-03-31 |
$-144 |
| 2022-12-31 |
$-144 |
| 2022-09-30 |
$-143 |
| 2022-06-30 |
$-142 |
| 2022-03-31 |
$-141 |
| 2021-12-31 |
$-139 |
| 2021-09-30 |
$-137 |
| 2021-06-30 |
$-135 |
| 2021-03-31 |
$-134 |
| 2020-12-31 |
$-132 |
| 2020-09-30 |
$-130 |
| 2020-06-30 |
$-128 |
| 2020-03-31 |
$-126 |
| 2019-12-31 |
$-123 |
| 2019-09-30 |
$-121 |
| 2019-06-30 |
$-117 |
| 2019-03-31 |
$-115 |
| 2018-12-31 |
$-112 |
| 2018-09-30 |
$-110 |
| 2018-06-30 |
$-107 |
| 2018-03-31 |
$-104 |
| 2017-12-31 |
$-101 |
| 2017-09-30 |
$-99 |
| 2017-06-30 |
$-96 |
| 2017-03-31 |
$-94 |
| 2016-12-31 |
$-92 |
| 2016-09-30 |
$-90 |
| 2016-06-30 |
$-87 |
| 2016-03-31 |
$-86 |
| 2015-12-31 |
$-84 |
| 2015-09-30 |
$-83 |
| 2015-06-30 |
$-81 |
| 2015-03-31 |
$-80 |
| 2014-12-31 |
$-79 |
| 2014-09-30 |
$-78 |
| 2014-06-30 |
$-77 |
| 2014-03-31 |
$-76 |
| 2013-12-31 |
$-75 |
| 2013-09-30 |
$-75 |
| 2013-06-30 |
$-74 |
| 2013-03-31 |
$-73 |
| 2012-12-31 |
$-73 |
| 2012-09-30 |
$-71 |
| 2012-06-30 |
$-70 |
| 2012-03-31 |
$-68 |
| 2011-12-31 |
$-67 |
| 2011-09-30 |
$-67 |
| 2011-06-30 |
$-66 |
| 2011-03-31 |
$-65 |
| 2010-12-31 |
$-64 |
| 2010-09-30 |
$-62 |
| 2010-06-30 |
$-61 |
| 2010-03-31 |
$-60 |
| 2009-12-31 |
$-58 |
| 2009-09-30 |
$-47 |
| 2009-06-30 |
$-46 |
| 2009-03-31 |
$-44 |
| Sector |
Industry |
Market Cap |
Revenue |
| Construction |
Engineering - Research & Development Services |
$0.074B |
$0.012B |
|
BioLargo Inc. is a cleantech and life sciences innovator and engineering services solution provider. The company's core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs. BioLargo Inc. is based in WESTMINSTER, CA.
|
